.Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascula.C08CA05_Nifedipine.Nifedipine

Information

Nifedipine is a dihydropyridine calcium channel blocker primarily used for the treatment of hypertension and angina pectoris. It causes vasodilation by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle. It is an approved drug and remains widely used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after a single oral immediate-release dose.

References

1. Renwick, AG, et al., & George, CF (1988). The pharmacokinetics of oral nifedipine--a population study. British journal of clinical pharmacology 25(6) 701–708. DOI:10.1111/j.1365-2125.1988.tb05256.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3203042

2. Fattinger, K, et al., & Follath, F (1991). Population pharmacokinetics of quinidine. British journal of clinical pharmacology 31(3) 279–286. DOI:10.1111/j.1365-2125.1991.tb05531.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/2054269

3. Castañeda-Hernández, G, et al., & Flores-Murrieta, FJ (1993). Pharmacokinetics of oral nifedipine in different populations. Journal of clinical pharmacology 33(2) 140–145. DOI:10.1002/j.1552-4604.1993.tb03934.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/8440762

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)